SCHEMBL3464666

SCHEMBL3464666

COCCCN1CCOc2ccc(COC3CNCC(O)C3c3ccc(Oc4cccc(OCCOC)c4)cc3)cc21

nearest known ligand 0.44

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
REN P00797 16/20 0.44
HTR1A P08908 1/20 0.33
SLC6A4 P31645 1/20 0.33
AXL P30530 1/20 0.32
MERTK Q12866 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8430145 1.00 REN (0.44) RENHTR1ASLC6A4AXLMERTK
SCHEMBL13161138 1.00 REN (0.44) RENHTR1ASLC6A4AXLMERTK
SCHEMBL8434744 0.98 REN (0.47) RENAXLMERTK
SCHEMBL3277915 0.98 REN (0.47) RENAXLMERTK
SCHEMBL13161131 0.98 REN (0.47) RENAXLMERTK
SCHEMBL13161120 0.96 REN (0.43) RENAXLMERTKGRM5
SCHEMBL4668025 0.96 REN (0.43) RENAXLMERTKGRM5
SCHEMBL13161112 0.95 REN (0.42) RENAXLMERTKGRM5
SCHEMBL3274355 0.95 REN (0.42) RENAXLMERTKGRM5
SCHEMBL8428845 0.95 REN (0.42) RENAXLMERTKGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799779-B2 Substituted piperidines as renin inhibitors NOVARTIS AG (CH) 2010-09-21 US disclosed
US-20090306064-A1 Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2009-12-10 US disclosed
EP-1987834-A2 Substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2008-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306064-A1 Substituted Piperidines as Renin Inhibitors REN, AGTR1, ACE REN 1/4885HTR1A 747/4885SLC6A4 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.